Drug reference

Cannabis extract

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1212

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Adjunct in moderate to severe spasticity in multiple sclerosis (specialist use only) ▶BY BUCCAL ADMINISTRATION ▶Adult: (consult product literature)

PDF page 1212

Contra Indications

Family history of psychosis. history of other severe psychiatric disorder. personal history of psychosis

PDF page 1212

Cautions

History of epilepsy. signiﬁcant cardiovascular disease

PDF page 1212

Safety

Interactions

→Appendix 1: cannabidiol. dronabinol

PDF page 1212

Side Effects

▶Common or very common Appetite abnormal. balance impaired. concentration impaired. constipation. depression. diarrhoea. disorientation. dizziness. drowsiness. dry mouth. dysarthria. euphoric mood. feeling drunk. malaise. memory loss. nausea. oral disorders. perception altered. taste altered. vertigo. vision blurred. vomiting ▶Uncommon Abdominal pain upper. delusions. hallucinations. hypertension. palpitations. paranoia. pharyngitis. suicidal ideation. syncope. tachycardia. throat irritation. tooth discolouration

PDF page 1212

Conception And Contraception

Manufacturer recommends effective contraception during and for 3 months after treatment in men and women.

PDF page 1212

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risks.

PDF page 1212

Breast Feeding

Avoid—present in milk.

PDF page 1212

Hepatic Impairment

Manufacturer advises avoid in moderate to severe impairment (risk of accumulation with chronic dosing)—no information available.

PDF page 1212

Renal Impairment

Monitoring Manufacturer advises more frequent monitoring in signiﬁcant renal impairment—possible risk of prolonged or enhanced effect.

PDF page 1212

Monitoring Requirements

Monitor oral mucosa— interrupt treatment if lesions or persistent soreness.

PDF page 1212

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Spray EXCIPIENTS: May contain Propylene glycol ▶Sativex (Bayer Plc) Cannabidiol 2.5 mg per 1 dose, Dronabinol 2.7 mg per 1 dose Sativex oromucosal spray | 270 dose P £300.00 DT = £300.00 d MUSCLE RELAXANTS › CENTRALLY ACTING

PDF page 1212

Clinical care

Patient And Carer Advice

Driving and skilled tasks For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including cannabis, see Drugs and driving under Guidance on prescribing p. 1.

PDF page 1212

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1212

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Cannabis extract

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1212

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Adjunct in moderate to severe spasticity in multiple sclerosis (specialist use only) ▶BY BUCCAL ADMINISTRATION ▶Adult: (consult product literature)

PDF page 1212

Contra Indications

Family history of psychosis. history of other severe psychiatric disorder. personal history of psychosis

PDF page 1212

Cautions

History of epilepsy. signiﬁcant cardiovascular disease

PDF page 1212

Safety

Interactions

→Appendix 1: cannabidiol. dronabinol

PDF page 1212

Side Effects

PDF page 1212

Conception And Contraception

Manufacturer recommends effective contraception during and for 3 months after treatment in men and women.

PDF page 1212

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risks.

PDF page 1212

Breast Feeding

Avoid—present in milk.

PDF page 1212

Hepatic Impairment

Manufacturer advises avoid in moderate to severe impairment (risk of accumulation with chronic dosing)—no information available.

PDF page 1212

Renal Impairment

Monitoring Manufacturer advises more frequent monitoring in signiﬁcant renal impairment—possible risk of prolonged or enhanced effect.

PDF page 1212

Monitoring Requirements

Monitor oral mucosa— interrupt treatment if lesions or persistent soreness.

PDF page 1212

Dose and formulations

Medicinal Forms

PDF page 1212

Clinical care

Patient And Carer Advice

Driving and skilled tasks For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including cannabis, see Drugs and driving under Guidance on prescribing p. 1.

PDF page 1212

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1212

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.